The observed specific activity of Pin-EGFR-armed eNK cells on multiple patient-derived GBM cells suggests that this product may be a new therapeutic option for patients with glioblastoma expressing EGFR or the EGFRvIII variant or diagnosed with an amplification of wild-type EGFR. This evidence concerns the gene EGFR and glioblastoma.